Nuvaxovid XBB.1.5▼ dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601)

Terms and Conditions

This website has been developed as a service of Novavax, Inc. ("Novavax"). The information on this website may become out of date over time. Nothing on this website should be construed as the giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. Novavax accepts no liability for the accuracy nor completeness nor use of, nor any liability to update, the information contained on this website.

THESE MATERIALS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.

This website may link you to other websites on the Internet, including the websites of Novavax affiliates in other countries. Novavax cannot take responsibility for information found on third-party websites. While Novavax attempts to provide links only to third-party websites that comply with all applicable laws and regulations and Novavax's standards, the content on these third-party websites is subject to change without notice to Novavax. Novavax accepts no liability for any information or opinion contained in any third-party website. Nothing on this website constitutes an invitation or offer to invest or deal in the securities of Novavax. In particular, actual results and developments may be materially different from any forecast, opinion or expectation expressed on this website and the past performance of the price of securities must not be relied on as a guide to their future performance.